These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. How much successful are the medicinal chemists in modulation of SIRT1: A critical review. Kumar A; Chauhan S Eur J Med Chem; 2016 Aug; 119():45-69. PubMed ID: 27153347 [TBL] [Abstract][Full Text] [Related]
5. Carprofen analogues as sirtuin inhibitors: enzyme and cellular studies. Mellini P; Carafa V; Di Rienzo B; Rotili D; De Vita D; Cirilli R; Gallinella B; Provvisiero DP; Di Maro S; Novellino E; Altucci L; Mai A ChemMedChem; 2012 Nov; 7(11):1905-8. PubMed ID: 24155041 [TBL] [Abstract][Full Text] [Related]
6. Salermide, a Sirtuin inhibitor with a strong cancer-specific proapoptotic effect. Lara E; Mai A; Calvanese V; Altucci L; Lopez-Nieva P; Martinez-Chantar ML; Varela-Rey M; Rotili D; Nebbioso A; Ropero S; Montoya G; Oyarzabal J; Velasco S; Serrano M; Witt M; Villar-Garea A; Imhof A; Mato JM; Esteller M; Fraga MF Oncogene; 2009 Feb; 28(6):781-91. PubMed ID: 19060927 [TBL] [Abstract][Full Text] [Related]
9. Measurement of the cellular deacetylase activity of SIRT1 on p53 via LanthaScreen® technology. Robers MB; Loh C; Carlson CB; Yang H; Frey EA; Hermanson SB; Bi K Mol Biosyst; 2011 Jan; 7(1):59-66. PubMed ID: 20931131 [TBL] [Abstract][Full Text] [Related]
10. SIRT1-independent mechanisms of the putative sirtuin enzyme activators SRT1720 and SRT2183. Huber JL; McBurney MW; Distefano PS; McDonagh T Future Med Chem; 2010 Dec; 2(12):1751-9. PubMed ID: 21428798 [TBL] [Abstract][Full Text] [Related]
11. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. Mai A; Valente S; Meade S; Carafa V; Tardugno M; Nebbioso A; Galmozzi A; Mitro N; De Fabiani E; Altucci L; Kazantsev A J Med Chem; 2009 Sep; 52(17):5496-504. PubMed ID: 19663498 [TBL] [Abstract][Full Text] [Related]
12. The critical role of the class III histone deacetylase SIRT1 in cancer. Liu T; Liu PY; Marshall GM Cancer Res; 2009 Mar; 69(5):1702-5. PubMed ID: 19244112 [TBL] [Abstract][Full Text] [Related]
13. Sirtuins and p53. van Leeuwen I; Lain S Adv Cancer Res; 2009; 102():171-95. PubMed ID: 19595309 [TBL] [Abstract][Full Text] [Related]
14. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Knutson MD; Leeuwenburgh C Nutr Rev; 2008 Oct; 66(10):591-6. PubMed ID: 18826454 [TBL] [Abstract][Full Text] [Related]
15. Therapeutic potential of activators and inhibitors of sirtuins. Balcerczyk A; Pirola L Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588 [TBL] [Abstract][Full Text] [Related]